Evaluation of a Community Pharmacist-Led Intervention Program for Early Detection of Gastrointestinal Adverse Events of Dipeptidyl Peptidase-4 Inhibitors: A Multicenter, Non-Randomized Comparative Study.

Ayana Funabashi, Hitoshi Ito, Mamoru Maeda, Yoshitaka Hasegawa, Ryota Tsukioka, Mitsuko Onda

Abstract read

In one paragraph

Article in Pharmacy (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Beyond prescriptions: an analysis of patient journey, self-management adherence, and unmet needs in type 2 diabetes.BMC health services research · 2026
Article
Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists.Pharmaceuticals (Basel, Switzerland) · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ayana FunabashiAIN PHARMACIEZ INCORPORATED 1F, 2-7-1, Daigakumachi, Takatsuki 569-8686, Osaka, Japan.

Hitoshi ItoAIN HOLDINGS INCORPORATED JR South Shinjuku Building 11F, 2-1-5 Yoyogi, Shibuya, Tokyo 151-0053, Japan.

Mamoru MaedaAIN HOLDINGS INCORPORATED JR South Shinjuku Building 11F, 2-1-5 Yoyogi, Shibuya, Tokyo 151-0053, Japan.

Yoshitaka HasegawaAIN HOLDINGS INCORPORATED JR South Shinjuku Building 11F, 2-1-5 Yoyogi, Shibuya, Tokyo 151-0053, Japan.

Ryota TsukiokaAIN HOLDINGS INCORPORATED JR South Shinjuku Building 11F, 2-1-5 Yoyogi, Shibuya, Tokyo 151-0053, Japan.

Mitsuko OndaFaculty of Pharmacy, Department of Social and Administrative Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1, Nasahara, Takatsuki 569-1094, Osaka, Japan.ORCID 0000-0002-5855-2727

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this multicenter, nonrandomised comparative study, we evaluated the potential effectiveness of a program to promote the safe use of dipeptidyl peptidase-4 (DPP-4) inhibitors led by community pharmacists. The program facilitated early detection of gastrointestinal adverse events (GIAEs) in patients newly prescribed DPP-4 inhibitors and facilitated timely communication with physicians. Community pharmacists reviewed patient conditions and provided relevant information to physicians as needed. GIAE monitoring based on the program was conducted in 35 patients at 10 pharmacies in Japan (intervention group) between March and August 2024. The proportion of pharmacist interventions was compared with that in 451 patients from March to August 2023, before program implementation (baseline cohort). The primary outcome, pharmacist intervention rate, was significantly higher in the intervention group (5 out of 35 patients, 14.3%) than in the baseline cohort (0 out of 451 patients, 0.0%) (

Indexed as

community pharmacistdiabetes mellitusdipeptidyl peptidase-4 inhibitorsfollow-up caregastrointestinal adverse eventstracing report

Identifiers

PMID40981239

DOI10.3390/pharmacy13050119

PMCPMC12452381

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.